Zotefoams PLC High-performance foam in medical facility doors
27 Abril 2023 - 1:00AM
RNS Non-Regulatory
TIDMZTF
Zotefoams PLC
27 April 2023
27 April 2023
Zotefoams plc
("Zotefoams" or "Group")
Agreement to supply high-performance foam for use in medical
facility doors
Zotefoams, a world leader in cellular materials technology, is
pleased to announce an agreement with Kennon Products (Wyoming,
USA) to supply ZOTEK(R) F high-performance foam for use in Kennon's
newest ligature-resistant patient safety door, broadening the scope
of application for this material. So-called breakaway doors are
used in medical facilities to protect vulnerable patients from
self-harm while affording privacy.
Produced exclusively by Zotefoams and manufactured from PVDF
(polyvinylidene fluoride), ZOTEK F is best-known as a disruptive
material that has enabled airframe manufacturers and airlines to
reduce carbon consumption by shedding significant weight from
aircraft interiors. Equally important are the safety credentials of
the material: PVDF is inherently inert, and Zotefoams' proprietary
method of foam manufacture does not affect that essential purity.
Accordingly, ZOTEK F achieves the highest ratings for its Fire,
Smoke and Toxicity (FST) properties and also exhibits excellent
resistance to mould and bacteria growth.
Safety is the foremost consideration in the design of the Kennon
Door 2.0. The softness of ZOTEK F and its light weight combine with
breakaway magnetic hinges to save lives, as do its resistance to
flame and - in the event of ignition - low smoke output. The
durable design of the door also enhances the look of any
facility.
Kennon achieved its primary objective, that of developing a door
that achieves the USA's new National Fire Protection Association
NFPA-286 certification, which is required for facility operators
wishing to meet certain fire prevention guidelines.
"The unique properties of ZOTEK F foam are a key reason for our
anti-ligature doors meeting the NFPA-286 standard," said Kennon
CEO, Joe Wright. "Our partnership with Zotefoams has been a mutual
success and together we're helping to save lives in behavioural
health hospitals."
David Stirling, Zotefoams Group CEO, commented, "We were pleased
to work closely with Kennon on this project, selecting and testing
various ZOTEK F materials, while providing support and insight
based on our previous experience of aviation applications and flame
testing.
"This application has produced another 'first' for ZOTEK F and
demonstrates the potential of the material to deliver benefits well
beyond its current core markets of aviation and aerospace."
* ENDS *
Enquiries:
Zotefoams plc +44 (0) 208 664 1600
David Stirling, Group CEO
Gary McGrath, Group CFO
IFC Advisory (Financial PR
& IR) +44 (0) 203 934 6630
Graham Herring
Tim Metcalfe
Zach Cohen
About Zotefoams plc
Zotefoams plc (LSE - ZTF) is a world leader in cellular
materials technology delivering optimal material solutions for the
benefit of society. Utilising a variety of unique manufacturing
processes, including environmentally friendly nitrogen expansion
for lightweight AZOTE(R) polyolefin and ZOTEK(R) high-performance
foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses
its own cellular materials to manufacture T-FIT(R) advanced
insulation for demanding industrial markets. Zotefoams also owns
and licenses patented microcellular foam technology to reduce
plastic use in extrusion applications and for ReZorce(R)
mono-material recyclable barrier packaging.
Zotefoams is headquartered in Croydon, UK, with additional
manufacturing sites in Kentucky, USA and Brzeg, Poland (foam
manufacture), Oklahoma, USA (foam products manufacture and
conversion), Massachusetts, USA, Stilling, Denmark (microcellular
foam technology) and Jiangsu Province, China (T-FIT).
www.zotefoams.com
AZOTE(R) , ZOTEK(R) , ReZorce(R) and T-FIT(R) are registered
trademarks of Zotefoams plc.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAIFMFTMTATBBJ
(END) Dow Jones Newswires
April 27, 2023 02:00 ET (06:00 GMT)
Zotefoams (LSE:ZTF)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Zotefoams (LSE:ZTF)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
